

26. Ameer, B.; Greenblatt, D. J. Lorazepam: a Review of its Clinical Pharmacological Properties and Therapeutic Uses. *Drugs* **1981**, *21* (3), 162–200.
27. Aulton, M. E.; Taylor, K. M. G., Eds. *Aulton's Pharmaceutics: The Design and Manufacture of Medicines*, 4th ed.; Churchill Livingstone: Edinburgh, U.K, 2013.
28. Hussan, S. D.; Santanu, R.; Verma, P.; Bhandari, V. A Review on Recent Advances of Enteric Coating. *IOSR J. Pharm.* **2012**, *2* (6), 5–11.
29. a. Senel, S.; Hincal, A. A. Drug Permeation Enhancement via Buccal Route: Possibilities and Limitations. *J. Control. Release* **2001**, *72*, 1–3. 133–144.
b. van Hoogdalem, E. J.; de Boer, A. G.; Breimer, D. D. Intestinal Drug Absorption Enhancement: An Overview. *Pharmacol. Ther.* **1989**, *44* (3), 407–443.
30. Merisko-Liversidge, E.; Liversidge, G. G.; Cooper, E. R. Nanosizing: a Formulation Approach for Poorly-water-soluble Compounds. *Eur. J. Pharm. Sci.* **2003**, *18*, 113–120.
31. Liversidge, G. G.; Cundy, K. C. Particle Size Reduction for Improve Ment of Oral Bio-availability of Hydrophobic Drugs: I. Absolute Oral Bioavailability of Nanocrystalline Danazol in Beagle Dogs. *Int. J. Pharm.* **1995**, *125* (1), 91–97.
32. a. Chen, H.; Khemtong, C.; Yang, X.; Chang, X.; Gao, J. Nanonization Strategies for Poorly Water-soluble Drugs. *Drug Discovery Today* **2011**, *16*, 7–8. 354–360.
b. Sushant, S.; Archana, K. Methods of Size Reduction and Factors Affecting Size Reduction in Pharmaceutics. *Int. Res. J. Pharm.* **2013**, *4* (8), 57–64.
33. a. Shende, P.; Shrawne, C.; Gaud, R. S. Multi-layer Tablet: Current Scenario and Recent Advances. *Int. J. Drug Deliv.* **2012**, *4*, 418–426.
b. Yadav, G.; Bansal, M.; Thakur, N.; Khare, S.; Khare, P. Multilayer Tablets and Their Drug Release Kinetic Models for Oral Controlled Drug Delivery System. *Middle-East J. Sci. Res.* **2013**, *16* (6), 782–795.
34. a. Herrlich, S.; Spieth, S.; Messner, S.; Zengerle, R. Osmotic Micropumps for Drug Delivery. *Adv. Drug Deliv. Rev.* **2012**, *64* (14), 1617–1627.
b. Ghosh, T.; Ghosh, A. Drug Delivery through Osmotic Systems – an Overview. *J. Appl. Pharma. Sci.* **2011**, *1* (2), 38–49.
35. Code of Federal Regulations Title 21, Chapter 1, Subchapter D, Part 312, Subpart B, Section, 312.23.
36. Caldwell, G. W.; Masucci, J. A.; Yan, Z.; Hageman, W. Allometric Scaling of Pharmacokinetic Parameters in Drug Discovery: Can Human CL, Vss and T1/2 Be Predicted from In-vivo Rat Data? *Eur. J. Drug Metab. Pharmacokinet.* **2004**, *29* (2), 133–143.
37. Ivy, S. P.; Siu, L. L.; Garrett-Mayer, E.; Rubinstein, L. Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. *Clin. Cancer Res.* **2010**, *16*, 1726–1736.
38. Eisenhauer, E. A.; O'Dwyer, P. J.; Christian, M.; Humphrey, J. S. Phase I Clinical Trial Design in Cancer Drug Development. *J. Clin. Oncol.* **2000**, *18* (3), 684–692.
39. Chan-Tack, K. M.; Struble, K. A.; Morgensztejn, N.; Murray, J. S.; Gulick, R.; Cheng, B.; Weller, I.; Miller, V. HIV Clinical Trial Design for Antiretroviral Development: Moving Forward. *AIDS* **2008**, *22* (18), 2419–2427.
40. Ip, S.; Paulus, J. K.; Balk, E. M.; Dahabreh, I. J.; Avendano, E. E.; Lau, J. Role of Single Group Studies in Agency for Healthcare Research and Quality Comparative Effectiveness Reviews. Publication No. 13-EHC007-EF *Agency for Healthcare Research and Quality Publication* **January 2013**.
41. Vasan, R. S. Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations. *Circulation* **2006**, *113*, 2335–2362.
42. Strimbu, K.; Tavel, J. A. What Are Biomarkers? *Curr. Opin. HIV AIDS* **2010**, *5* (6), 463–466.
43. Hay, M.; Thomas, D. W.; Craighead, J. L.; Economides, C.; Rosenthal, J. Clinical Development Success Rates for Investigational Drugs. *Nat. Biotechnol.* **2014**, *32*, 40–51.
44. Roy, A. S. A. Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials. In *Project FDA Report 5, Manhattan Institute for Policy Research*; 2012; pp 1–8.